Sage Journals: Discover world-class research

Abstract

The integration of biotechnology into the traditional regulatory framework of drugs and biologics has produced the need to reexamine traditional definitions and the way in which products of biotechnology are handled by regulatory agencies. The concept that biological products can only be adequately addressed by rigid process control, coupled with reliance on biological assays, has to be readdressed in the light of scientific advances in physicochemical characterization. At the same time, it is necessary to prevent the introduction of new quality control procedures without adequate discussion. Preclinical safety testing of biotechnology products is continually evolving and should not be obstructed by premature guidelines. Finally, the emergence of the biotechnology industry has catalyzed changes in drug regulation worldwide, with major impact on the regulation of synthetic products.

Keywords

Regulation Biotechnology Pharmaceuticals Quality control Toxicology

Get full access to this article

View all access options for this article.

References

US Department of Health, Education and Welfare, Public Health Service: Legislative History of the Regulation of Biological Products. Division and Biologics Standards, National Institutes of Health, 1971.

Goeddel

Heynecker

Hozumi

: Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature 1979; 281: 544–548.

Lasagna

: Clinical testing of products prepared by biotechnology. Regul Toxicol Pharmacol 1986; 6: 385–390.

Lucas-Lenard

Lipmann

: Protein biosynthesis, in Snell

Boyer

Meister

(eds): Annu Rev Biochem 1971; 40:409–448.

Mattaliano

Rosa

Foeller

: Analysis of recombinant proteins — Current trends and practical limits in analytical stringency, in Walsh

(ed): Methods in Protein Sequence Analysis, 1986, Clifton, NJ, Humana Press, 1987, pp 79–95.

Wingfield

Graber

Raothovvan

: N-terminal-methionylated interleukin-1β has reduced receptor-binding affinity. FEBS LETT, 1987; 215:160–164.

Petricianni

: Old issues confront biotechnology and new products. Vaccine, 1984; 2:235–236.

European Federation of Pharmaceutical Industry Associations. Preclinical safety testing of polypeptide medicinal products derived from biotechnology: First approaches to safety evaluation. EFPIA, Brussels, 1987.

Committee for Proprietary Medicinal Products: Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Commission of the European Communities, Brussels, 1987, Draft III/407/87-EN, April 1987, Revision 3.

10.

Collins

Kaffka

: Structure-function analysis of human interleukin-2: Identification of amino acid residues required for biological activity. J Biol Chem 1987; 262: 5723–5731.

11.

Council of the European Economic Communities: Council directive of 22 December 1986 on the approximation of national measures relating to the placing on the market of high-technology medicinal products, particularly those derived from biotechnology (87/22/EEC). Official Journal of the Economic Communities, 1987; 30:LIS:38–41.

12.

Clark

A J

Simons

Wilmut

: Pharmaceuticals from transgenic livestock. Trends Biotech 1987; 5: 20–24.

Regulatory Affairs Issues in Biotechnology

Abstract

Keywords

Get full access to this article

References